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The HIV-1 transmission bottleneck
Samuel Mundia Kariuki1,3,4, Philippe Selhorst2, Kevin K. Ariën5,6 and Jeffrey R. Dorfman1* 
Abstract 
It is well established that most new systemic infections of HIV-1 can be traced back to one or a limited number of 
founder viruses. Usually, these founders are more closely related to minor HIV-1 populations in the blood of the 
presumed donor than to more abundant lineages. This has led to the widely accepted idea that transmission selects 
for viral characteristics that facilitate crossing the mucosal barrier of the recipient’s genital tract, although the specific 
selective forces or advantages are not completely defined. However, there are other steps along the way to becom-
ing a founder virus at which selection may occur. These steps include the transition from the donor’s general circula-
tion to the genital tract compartment, survival within the transmission fluid, and establishment of a nascent stable 
local infection in the recipient’s genital tract. Finally, there is the possibility that important narrowing events may also 
occur during establishment of systemic infection. This is suggested by the surprising observation that the number of 
founder viruses detected after transmission in intravenous drug users is also limited. Although some of these steps 
may be heavily selective, others may result mostly in a stochastic narrowing of the available founder pool. Collectively, 
they shape the initial infection in each recipient.
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Background
It has long been understood that the HIV-1 of the donor 
often exhibits a reduced viral diversity following trans-
mission to a new host [1, 2]. More recently, about ten 
years ago, it became clear that this narrowing is usually 
very sharp, with only one or a very few viruses establish-
ing a disseminated infection in the newly infected indi-
vidual despite the high diversity of HIV-1 populations 
in most donors [3–8]. This phenomenon has become 
termed the “transmission bottleneck” of HIV-1 and 
is incompletely understood. Key questions about the 
precise nature of the selective events that result in the 
observed bottleneck remain unanswered.
The genetic bottleneck stems from physical and immu-
nological conditions that prevent most variants within 
the incoming viral populations from establishing infec-
tion in a new host [9] and is reflected by the low effi-
ciency of HIV-1 transmission from a single sexual 
exposure [4]. Thus successful infections in a new host 
frequently results from the dissemination of only a single 
variant after sexual transmission, in approximately 80% 
of heterosexual transmissions [6, 8], approximately 75% 
of transmissions in men who have sex with men (MSM) 
[10–12], approximately 70% of transmissions in mother-
to-child [13] and 40–80% of transmissions in intravenous 
drug users (IVDU) [12, 14, 15].
Here we review the multiple steps at which selection 
potentially occurs, from donor compartments to estab-
lished infection in the recipient. We look in the context 
of transmitted/founder (T/F) or acute virus genotypic 
and phenotypic traits identified and reported to date. 
Although there may be steps that result mostly in a sto-
chastic narrowing of the available founder pool, some 
of the steps are likely to be heavily selective. This is sug-
gested by the fact that the recipient’s disseminated infec-
tion is almost always derived from a minor variant within 
the diverse quasispecies of the donor [3, 4]. Increased risk 
of breakthrough of multiple variants after sexual trans-
mission is mostly associated with factors that both com-
promise the genital mucosa and attract HIV-1 target cells 
e.g. genital ulceration and sexually transmitted infection 
(STI) [5]. This suggests that damage of the physical bar-
rier of the mucosal surface and/or recruitment of target 
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cells for HIV-1 infection increase the risk of subsequent 
systemic infection.
Importantly, there is also evidence suggesting that 
the HIV-1 populations compartmentalize between gen-
eral circulation and genital tract [16–21], and factors in 
semen [22] could select for or against particular HIV-1 
traits. Thus, part of the bottleneck effect may already 
have occurred before transmission to a new donor. Addi-
tionally, the high rate of single variant populations early 
in infection in IVDU [12, 14, 15] may reflect substantial 
selection during the establishment of new systemic infec-
tions, after the HIV-1 has crossed the mucosal barrier. 
Thus, the HIV-1 transmission bottleneck may collectively 
describe events along every stage during the transmis-
sion process from the donor’s blood, all the way through 
to establishment of a stable, disseminated infection in the 
recipient. This is shown in schematic form in Fig. 1.
Potential intra‑donor selection during the 
transition from systemic circulation to the genital 
tract
Originally, it was thought that the virions and infected 
cells found in semen are directly imported from the blood 
[23]. However various studies have now shown that the 
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Fig. 1 A schematic of some of the steps of sexual transmission and IVDU transmission of HIV-1 in which selective or stochastic narrowing of the 
HIV-1 population is possible. Blue circles genital tract; blue arrows steps of sexual transmission; Red circles blood/general circulation; red arrow trans-
mission from parenteral exposure, e.g. IVDU exposure
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genital tract constitutes a distinct viral compartment that 
locally produces viral particles and infected cells presum-
ably under a different selective milieu than in the general 
circulation [24–27]. As a result, the viral quasispecies in 
the genital compartment are related to, yet distinct from 
that in blood. Therefore, during a transmission event, the 
viruses to which the recipient is initially exposed may 
already differ from the viruses found in the blood of the 
donor. Most data compare viral populations in semen to 
those in the blood circulation; however, limited data exist 
to suggest the possibility of a similar effect in the female 
genital tract compared to the blood circulation of the 
same donor [17].
Although the viruses in the genital compartment 
are thought to move back and forth between the blood 
and the genital compartment [20, 28, 29], generally this 
movement appears limited and doesn’t seem to negate 
the reduced genetic diversity observed in the genital 
tract [18]. Individual infected CD4+ cells or virions from 
the blood may infiltrate into pockets of uninfected tar-
get cells in the genital tract [30] to generate local foci of 
infection or even sustained, autonomous virus replication 
which would lead to clonal amplification or full compart-
mentalization of virus in the genital tract [18]. Studies of 
the male genital tract in macaques and humans indeed 
demonstrated that SIV and HIV-1 can replicate in leu-
kocytes within the testes, epididymis, prostate and semi-
nal vesicles during all stages of infection [31, 32]. These 
leukocytes, mainly T lymphocytes and to a lesser extent 
macrophages, are localized in the stroma and secretory 
epithelium of these organs. Infection of these cells could 
lead to the release of free viral particles and infected cells 
in the lumen and thus in the seminal plasma during ejac-
ulation [33]. Prostate and seminal vesicles are likely the 
main source of cell-free HIV-1 in semen, as they display 
higher levels of infection than the epididymis and the tes-
tes [32]. This is supported by the fact that vasectomy has 
little or no effect on seminal viral loads [30, 34].
Factors that may influence the transmission 
bottleneck in genital fluid
The genital fluid includes semen in males and cervical 
vaginal fluid in females. Genital fluids are known to con-
tain proteins that can enhance or reduce the viral infec-
tivity. In semen for example, a well-known enhancer of 
viral infectivity is the semen-derived enhancer of virus 
infectivity (SEVI) [22, 35]. SEVI is made up of peptides 
found in semen that aggregate into amyloid fibrils and 
are capable of enhancing virus attachment to target cells 
and increase infectivity by up to 400,000-fold [22] using 
a mechanism that involves cationic charges of the fibrils 
[36]. Studies are underway to determine whether the 
same viral enhancement happens in vivo.
Looking at pre-infection in women, inflammatory 
cytokines have been shown to enhance HIV-1 acquisition 
[37, 38]. Furthermore, it has also recently been shown 
that high levels of inflammation may select for transmis-
sion of viruses that are less infectious [39]. These effects 
likely reflect an impact of inflammatory cytokines upon 
the transmission bottleneck.
In HIV-infected men, transmission fluid contains both 
cell-free virus from the seminal plasma and cell-associ-
ated virus from seminal cells. The latter are usually the 
most abundant HIV-susceptible host cell in semen as 
seminal CD4+ T lymphocytes are often depleted dur-
ing chronic infection [18]. The relative contribution of 
cell-associated vs cell-free seminal virus towards trans-
mission is yet to be resolved. One study supports the 
transmission of cell-free virus as opposed to cell-asso-
ciated virus [40], although this interpretation has been 
questioned [41]. Interestingly, viral variants isolated from 
seminal leukocytes are sometimes phylogenetically dis-
tinct from cell-free virions found in the seminal plasma 
[21] indicating that they may differ phenotypically and 
in their transmission potential. A discrepancy is often 
observed between the number of infected leukocytes and 
the cell-free viral load in semen [42]. It appears therefore 
that the HIV-infected cells in semen are not the primary 
source of cell-free virus in seminal plasma and that prob-
ably distinct sources contribute to either cell-free or cell-
associated HIV-1 shedding in semen. Ordinarily, it is 
expected that cell-associated virus would represent older 
partially archived, more stable viral populations while the 
cell-free viruses in plasma would represent recently pro-
duced viruses, based upon the very short half-life of cell-
free virus in blood or transmission fluids [43]. One would 
expect then that if the majority of transmitted viruses 
originated from infected seminal cells, that these would 
resemble earlier viruses in the donor. While this has been 
reported in a study by Redd et al. [44], the inferred donor 
ancestral virus identified in the recipient was shown to 
originate from blood but there was no analysis of virus 
from the genital compartments to trace as best as pos-
sible the steps from blood to transmission.
Likely bottleneck while crossing the recipient 
mucosal barrier
The mucosa of the vagina consists of a multilayered, 
stratified squamous epithelium made up of four zones; 
basal, squamous, granular and cornified layers [45]. As 
this mucosa develops from the basal layers, cells become 
more flat and keratinized which restrict passive diffu-
sion of materials through it, including HIV-1 [46]. The 
ectocervix has a similar profile but the endocervix is 
composed of a single layer of columnar epithelium cov-
ered with mucus. The mucus on these cells provides a 
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protective barrier to infection, i.e. it forms a physical 
barrier in which virus particles can get trapped but also 
contains antiviral factors like secretory leukocyte pro-
tease inhibitor [47] and SDF-1 which is a natural ligand 
for CXCR4 [48]. The transformation zone that divides 
the endocervix and the ectocervix, has been suggested to 
be the most vulnerable region of the recipient for HIV-1 
to gain entry. However, it has been shown that the virus 
can still establish a systemic infection when macaque 
blind vagina pouches after hysterectomy are exposed to 
cell-free virus [46]. Physical abrasion of the mucosal epi-
thelium leads to an increased chance of infection. Pre-
sumably for this reason, the risk of infection through the 
anal sex route is approximately 10 times higher than via 
the vaginal route. This may be due to the relative fragil-
ity of the rectal mucosa, high risk of trauma during anal 
intercourse and/or more abundant HIV-1 target cells in 
the rectal mucosa. The established major sites of HIV-1 
transmission in males are the inner foreskin, tissue 
directly underneath the foreskin, and the urethra [49]. 
Presence of HIV-1 target cells on the inner foreskin ren-
ders it susceptible to HIV-1 infection [50–52]. Compared 
to the systemic circulation, a substantially larger pro-
portion of CD4+ T lymphocytes present in the foreskin 
express CCR5 coreceptors [53].
It is still not completely established to what extent an 
intact mucosal barrier selects for particular viral char-
acteristics over and above acting merely as a physi-
cal barrier to entry of most viruses. HIV-1 uses several 
mechanisms to cross the mucosal barriers of the recipi-
ents. It has been suggested that transcytosis and intraepi-
thelial transmigration of infected donor cells are the 
common mechanisms that the virus uses to access the 
submucosal tissues of the host. In addition to this, HIV-1 
can infect intra-epithelial Langerhans’ cells [54, 55] and 
also possibly intra-epithelial CCR5+ CCR7hi CD4+ T 
cells that can migrate in and out of the female genital 
tract and hence can disseminate infection [56].
Establishment of an initial focus of infection in the 
recipient’s mucosa
Once HIV-1 manages to breach the mucosal barrier, it 
will reach submucosal target cells such as dendritic cells, 
macrophages, and CD4+ T lymphocytes [57]. Although 
macrophages and dendritic cells can sustain produc-
tive infection, resting CD4+ T lymphocytes (i.e. with-
out markers of activation) are probably the first cells to 
be infected [58–60]. Studies in macaques have shown 
that small clusters of infected CD4+ T cells form in the 
mucosal tissue within 3–4  days after vaginal SIV expo-
sure [9]. Not surprisingly, these initial foci of infection are 
consistently found in the endocervix and transformation 
zone [9], although infection in other regions of the female 
genital tract does occur [61].
Viral exposure immediately increases MIP3-α/
CCL20 expression in the endocervical epithelium. 
This chemokine attracts plasmacytoid dendritic cells, 
which in turn recruit T cells and macrophages through 
MIP1-β [60]. Unfortunately this outside-in endocervi-
cal mucosal signaling system has the paradoxical adverse 
effect of recruiting new target cells to the site of infec-
tion. As a result, the innate immune response fuels the 
expansion of the initial founder population of infected 
cells, rather than preventing it [62]. Subsequently lym-
phatic drainage will spread this initial infection to the 
draining lymph nodes. Interstitial dendritic cells and 
possibly also macrophages are believed to facilitate this 
process [63]. DCs can trap HIV-1 on their cell surface 
through the expression of the C-type lectin DC-SIGN 
(specific ICAM3-grabbing non-integrin), which can bind 
gp120 [64]. Mannose receptors, which are expressed by 
macrophages, could play a similar role [65]. Like LCs, 
DCs are antigen presenting cells that migrate from the 
mucosal tissue to the lymph nodes to activate CD4+ and 
CD8+ lymphocytes. However, in contrast to langerin 
(CD207), binding of gp120 to DC-SIGN does not lead to 
HIV-1 degradation but rather preserves its infectivity for 
several days [63]. Virions are sequestered into surface-
accessible compartments of the DCs arising from mem-
brane invaginations [66]. Female to male transmission is 
less well studied; but, the initial foci of infection appear 
to occur most prominently in the inner foreskin in uncir-
cumcised [67] and urethra in circumcised and uncircum-
cised men [68]. Finally, although initial foci of infection in 
the genital tract are associated with successful transmis-
sion, they may not be a prerequisite. It remains possible 
that, through a compromised epithelium or transmigra-
tion, migratory immune cells carrying HIV as described 
above, could bypass the submucosa and directly establish 
infection in the lymph nodes or GALT. This mechanism 
is thought to explain systemic infection in the presence of 
high local concentrations of topical antiretroviral drugs 
that inhibit replication in the genital tissue [69].
The GALT and systemic dissemination
Upon arrival in the lymph nodes, HIV-1 exploits the 
immunological synapse that is normally formed between 
the antigen presenting DCs and naive CD4+ T cells, and 
transforms it into a virological synapse [70, 71]. Within 
this synapse, filopodial extensions emanating from CD4+ 
T lymphocytes make contact with the sequestered HIV-1 
virions thereby enhancing the efficiency of HIV-1 trans-
mission [71]. The establishment and expansion of the 
small founder population at the portal of entry and the 
subsequent dissemination to the draining lymph nodes 
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will eventually result in a self-propagating infection, 
which will spread to the secondary lymphoid tissues such 
as the spleen and GALT. This marks the end of a 7–10 day 
period, also known as the eclipse phase, in which virus is 
not yet detectable in the blood [72]. From then on, the 
infection is systemically apparent, leading to substantial 
depletion of gut CD4+ T cells during the acute phase and 
immune activation in the early asymptomatic phase.
Transmission bottleneck among intravenous drug 
users (IVDU)
There appears to be a substantial bottleneck during 
HIV-1 transmission among intravenous drug users 
(IVDUs). The disseminated infection seemed to be 
derived from a single variant in 40–80% of the transmis-
sions of new infections that were analyzed [12, 14, 15]. In 
an analysis that combined data from 5 different studies, 
only one T/F virus was detectable in 21 of 32 (66%) recent 
intravenous drug use-associated HIV-1 infections [12]. In 
aggregate, this is not different from the rate of infections 
traced to a single T/F virus following sexual transmission 
[12]. This strongly suggests that a substantial bottleneck 
at or near transmission exists during IVDU-associated 
transmission, in which there is no mucosal barrier to 
transmission.
The data used in this 5-study analysis almost exclu-
sively come from two research groups working in differ-
ent settings. In a North American cohort, 4/10 (40%) of 
the IVDU infections studied were traced to a single T/F. 
Although this is significantly lower than the rate of sin-
gle founder infections identified following sexual trans-
mission [14], this study nonetheless suggests that there 
remains a substantial bottleneck in IVDU transmission 
despite the absence of a physical barrier to transmission. 
In a Russian IVDU  cohort [15], 9/13 (69%) infections 
studied were traced to a single T/F. If this latter study is 
combined with unpublished analysis of 7 further infec-
tions from the same research group, then 16/20 (80%) of 
the IVDU infections studied were traced to a single T/F 
virus from this Russian cohort [12].
A substantial limitation to interpretation of these stud-
ies is that the size of the initial inoculum in IVDU cases 
is very difficult to estimate because, in part, it depends 
upon the volume of blood transferred during the use of 
shared needles and/or syringes, upon the infectiousness 
of the transferred virus and upon the donor’s viral load. 
The volume of blood drawn into the syringe to confirm 
that the needle is in a vein, will be highly variable (per-
haps 100 μl) and subsequently diluted by a variable vol-
ume of drugs in the syringe. In addition, practices such as 
booting (i.e. drawing blood into the syringe a second time 
and re-injecting it to rinse residual drug solution out of 
the dead-space) as well as flushing the needles with water 
before sharing, will all affect the final volume of donor 
blood that is transmitted to the recipient. In simulations, 
high dead space syringes transfer approximately 84  μl 
without rinsing and 1 μl of donor blood with rinsing, and 
low dead space syringes transfer ~2  μl without rinsing 
and much smaller volumes (<0.001  μl) with rinsing [73, 
74]. There is thus a wide range of possible transferred 
volumes, even under relatively controlled laboratory 
conditions.
A second factor that needs to be considered, will be the 
infectiousness of the HIV-1 in the retained donor blood. 
This will be affected by practices such as drug heating, the 
time between needle sharing, etc. Third, the size of the 
virus inoculum will be determined by the viral load of the 
donor. Viral loads of recently infected IVDUs [14, 15] and 
individuals infected by heterosexual transmission [75] are 
very often over 100,000 cp/ml, (100 cp/μl), in almost half 
of the study participants tested. Recently infected indi-
viduals may account for a disproportionately large frac-
tion of HIV-1 transmission under many conditions [76]. 
In any event, a log mean viral load of 16,000 cp/ml was 
calculated for North America and Europe (where these 
IVDU studies were conducted) using a large dataset 
derived mostly from chronically infected individuals [77]. 
These viral loads, particularly those of recently infected 
individuals, are high enough that the presence of multi-
ple variants in submicroliter volumes of blood is probably 
common. Despite this, new HIV-1 infections in IVDUs 
are very frequently traceable to a single founder virus, 
similar to what is observed for sexual transmission [12].
Another limitation to these studies is that it is not pos-
sible to rule out that some of the transmissions presumed 
to occur via the IVDU route could also have been actu-
ally transmitted sexually. In the case of the 20 transmis-
sions analyzed from Russian IVDUs, the transmission 
would almost certainly need to have been from another 
drug user (even if sexually transmitted), as the IVDU epi-
demic in the region is predominantly subtype A and the 
sexually transmitted epidemic is predominantly subtype 
B [78]. Finally, it is also not possible to rule out transmis-
sion of more than one very closely related virus. This may 
be more likely when the donor has an acute infection that 
has not fully diversified.
Despite these limitations, when aggregating all avail-
able data, the overall rate of new infections traced to a 
single variant in presumed IVDU transmission appears 
to be much higher than what can be expected from the 
estimated viral inoculum, and statistically indistinguish-
able from the rate in sexual transmission [12]. That there 
is a drastic drop in viral diversity from intravenous inoc-
ulum to new HIV-1 infection is supported by a study in 
rhesus macaques [79]. Five macaques were challenged 
with an intravenous dose of 2 × 105 viruses of one of two 
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viral isolates with diversity typical of early chronic HIV-1 
infection, plausibly a larger dose than is normally expe-
rienced during IVDU transmission. In three of the five 
macaques, the resulting infection was traced to between 
1 and 4 distinct variants. Thus, even under these con-
trolled conditions, the diversity of the HIV-1 infection 
from intravenous exposure is drastically reduced com-
pared to the diversity found in the inoculum.
To the extent that these data are explained by selection 
following IVDU inoculation, we must conclude that the 
mucosa of the genital tract are not absolutely required to 
produce a transmission bottleneck. We suggest that there 
may be substantial selection and/or stochastic narrow-
ing at the level of establishment of systemic infection (see 
Fig. 1).
If so, further thought must be applied to the role of the 
genital tract mucosa as a physical barrier to HIV-1 infec-
tion in sexual transmission. As already noted, analysis of 
an aggregate of currently available data suggest that the 
rate of new infections traceable to a single variant is not 
different between IVDU and sexual transmission [12]. 
However, there are substantial uncertainties associated 
with concluding that the mucosal barrier is not meaning-
ful to HIV-1 transmission. In particular, there are stud-
ies that suggest that genital mucosal surfaces do provide 
a substantial barrier to HIV-1 viral particles [3, 4, 61, 
80–85] that is likely to be meaningful to sexual transmis-
sion, although not essential for the transmission bottle-
neck. Nonetheless, in light of the substantial bottleneck 
associated with IVDU transmission, it is challenging to 
understand why sexual transmission to recipients with a 
range of STIs (such as syphilis and other ulcerating infec-
tions [86, 87], gonorrhea [88] and chlamydia [89]) leads 
to an increased risk of HIV-1 infection, and possibly an 
increased risk of infection by multiple HIV-1 variants 
[5, 90] (see below). Perhaps the effects of the STIs that 
actively promote the establishment of HIV-1 infection 
are the key, important effects rather than effects associ-
ated with compromise of the mucosal barrier.
Sexually transmitted infections and risk 
of multivariant transmission
Several types of sexually transmitted infections (STIs) 
increase the risk of HIV-1 infection in a potential recipi-
ent [38, 91]. There is also evidence for an association 
between presence of STIs and initial infection with 
multiple HIV-1 variants [5, 90]. However, neither study 
identified associations with particular STIs; they only 
observed associations with any vaginal/urethral dis-
charges in the recipients [5] or when grouping together 
occurrences of a number of STIs [90]. Other studies were 
unable to observe this association [92, 93]. It is possible 
that these latter studies were underpowered to detect the 
association; perhaps they failed to have a sufficient num-
ber of cases of the particular STIs most responsible for 
the observed increased risk of multivariant transmission. 
These effects could be mediated by breaks in the integ-
rity of the mucosal barrier [94], inflammatory cytokines 
[39] and/or availability of more, better or more accessi-
ble target cells for HIV-1 [91], particularly cells capable 
of sustaining HIV-1 infection and migration to other tis-
sues [54–56]. These possibilities may not necessarily be 
mutually exclusive. Because of the IVDU transmission 
evidence summarized above, we disfavor explanations 
associated with breaks in the integrity of the mucosal 
barrier.
Traits reported to be different 
between transmitted/founder (T/F) vs chronic 
viruses
Clear evidence that the T/F virus is selected from 
a highly diverse population present in a chronically 
infected donor [7, 8] has sparked substantial efforts to 
elucidate the characteristics selected for in T/F virus. 
Several research groups working on characterization 
of the T/F virus have identified traits that are different 
between T/F viruses and chronic viruses. This includes 
genotypic characteristics such as levels of envelope gly-
cosylation, length of envelope variable loops, being closer 
to an archived or consensus-like genotype, but also phe-
notypic characteristics such as CCR5 and CXCR4 utiliza-
tion, neutralization sensitivity, increased infectivity and 
replication capacity, Type I interferon (IFN) resistance, 
and susceptibility to capture by α4β7.
Transmission signature patterns in envelope sequences
Analysis of subtype B envelope sequences from acutely 
and chronically infected participants identified poten-
tial transmission signatures in the signal peptide, close 
to the CCR5 and CD4 binding sites and within the gp41 
cytoplasmic tail and cytoplasmic domains [11]. Using 
the most stringent approach, they found two differ-
ences. Sequences from acute infection were more likely 
to carry a histidine at position 12, and were more likely 
to lack a potential N-linked glycosylation (PNG) site at 
position 415 than those from chronic infection. Posi-
tion 12, within the signal peptide has been shown to be 
involved in trafficking of the nascent Env polypeptide to 
the endoplasmic reticulum and incorporation into viral 
particles and viral infectivity [95]. Changes in signal pep-
tides have previously been shown to influence viral infec-
tivity and Env expression [96]. Furthermore, sequences 
from chronically infected participants were more likely to 
carry threonine at position 415, resulting in the forma-
tion of a PNG site that was associated with sensitivity to 
neutralization [11]. It was suggested that the presence of 
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a PNG site at position 413–415 was selected against in 
acute viruses because it might impact viral infectivity or 
it could play a role in the mechanism of transmission.
Closer to archived or consensus‑like genotype
A study analyzing the envelope sequences of viruses 
sampled from genital fluid and blood plasma of trans-
mitting pairs, observed that the T/F virus sequences 
more closely resembled sequences from blood [17]. In 
addition, a study among Ugandan discordant couples 
showed that the transmitted virus sequences resembled 
those of ancestral variants, i.e. variants sampled earlier 
in time, as opposed to the contemporaneously circulat-
ing strains at the time of transmission in the donor [44]. 
This was attributed to sequestration of the virus in long-
lived reservoir cells that were infected early in the course 
of infection, but subsequently maintained at low levels 
in circulation as latently infected cells [44]. This work is 
supported by Carlson et  al. showing that there is a bias 
in recently transmitted viruses for consensus-like amino 
acids generated from Gag, Pol and Nef proteins in 137 
epidemiologically-linked transmitting pairs infected 
with subtype C viruses [97]. In addition, using infectious 
molecular clones generated from six-linked heterosex-
ual transmission pairs, it was shown that consensus-like 
genomes that were more sensitive to donor antibodies 
were selected for during transmission [98]. This group 
observed a selection bias towards consensus-like virus by 
measuring the pairwise distance of each variant to a data-
base-calculated subtype C consensus. T/F variants had 
reduced pairwise distances to consensus as compared 
to non-transmitted variants [98]. This idea of transmis-
sion of earlier variants is supported by Love et al., which 
showed that the initial founder virus circulates at low lev-
els, even long after transmission [99], suggesting that it or 
closely related viruses persist long into infection and may 
be available to transmit to new hosts. Taken together, the 
current understanding is that the T/F virus originates 
from a pool of variants that more closely resemble those 
that already existed before the transmission event than 
chronic viruses do.
Potential N‑glycosylation sites and loop lengths 
in Envelope
One important characteristic of the T/F virus is the dif-
ferential glycosylation levels of envelope. The glycans 
are carbohydrates that make up more than 50% of the 
HIV-1 envelope molecular weight. Initially, the glycans 
were thought to primarily influence immune escape, 
and are selected to shield antibody recognition site(s) 
[100]. However with subsequent studies, it became 
more and more clear that the extent of glycosylation 
has an influence on viral transmission and also involve 
structural characteristics. For example, they are part 
of the epitope of some broadly neutralizing antibodies 
[101–104]. Derdeyn et al. [105] first suggested that trans-
mitted viruses had fewer N-linked glycan sites because 
they observed that these viruses often had changes in 
the length of the variable loops. Similarly, it has been 
reported that T/F viruses from subtypes A, C and D carry 
more compact envelopes with fewer N-linked glycosyla-
tion sites [105–107]. The reduced glycosylation of the 
T/F virus has been linked to enhancement of binding of 
the virus to the α4β7 integrin which is a homing marker 
for CD4+ T cells to the GALT [108]. However, this trend 
for fewer PNG sites is not consistent across all studies. It 
has not been observed in subtype B [107, 109–111], sug-
gesting that phenotypes associated with one subtype or 
transmission route/conditions might not hold true for 
another. After transmission, the viral populations that 
subsequently evolve over the course of infection accumu-
late additional PNG sites [112]. A study done in a large 
cohort of subtype C non-linked acute and chronic viruses 
by Ping et  al. [106] showed a 5% overall difference in 
total glycosylation count between the acute and chronic 
viruses. Although this difference may appear small, it 
may reflect a much larger difference in a key subset of 
PNG sites that are relevant for increased transmission 
capacity. These changes may reflect subtle differences 
in the optimal structural characteristics of Env in T/F 
viruses vs the optimal structural characteristics of Env 
in chronic viruses. This could include interactions with 
α4β7 integrin or other receptors on distinct cell types, or 
type I interferon resistance (see below). They also plau-
sibly reflect a lesser need to evade antibodies very early 
when infection is first established.
The HIV-1 envelope gp120 has five hypervariable sub-
regions V1–V5 that are separated along the amino acid 
sequence by five constant regions C1–C5 and intercon-
nected by cysteine residues. They participate in several 
important functions in the evolution of the virus in the 
host. The V3 variable loop is the main determinant of 
coreceptor usage while the V1–V2 region participates 
substantially in masking the host neutralizing anti-
body target sites. These properties are influenced by the 
sequence length of the envelope, the changes in glyco-
sylation pattern and changes in amino acid sequences 
[113]. The T/F virus was found to have shorter variable 
regions as compared to their chronic counterparts [105, 
112–116] meaning that these viruses have more compact 
Env glycoproteins and there is a possibility they could 
be interacting more efficiently with the target cells in 
the genital mucosa [5, 107, 117, 118]. Additionally, dur-
ing early infection variants with shorter V1–V2 regions 
are seen to have a competitive growth advantage over the 
others. These variable loops then increase in length as 
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the virus goes through chronic infection and then decline 
once again in late stage infection. The change in length 
especially of the V1–V2 regions is due to deletions, 
insertions and many substitutions that appear to reflect 
escape from immune response of the host [114]. At the 
population level, during the HIV-1 epidemics it has been 
reported that the V1–V2 region has grown in length 
making the current viruses have moderately longer V1–
V2 [112, 114, 119] and more glycosylation sites [120] 
than historically older viruses.
Despite attempts with large data sets [97, 106], few 
strong associations between particular PNG sites or 
patterns of distinct PNG sites have been reported that 
are more frequent or less frequent in T/F isolates com-
pared to chronic isolates, and those that are reported are 
fraught with complex associations between the presence 
of different PNG sites (JRD, unpublished data). This sug-
gests a complexity that is poorly understood. For exam-
ple, the selective processes may affect particular PNG 
sites differently in different contexts, i.e. in different iso-
lates or different transmission modes or conditions. Also, 
different antibody responses may select for or against 
different PNG sites in different individuals, complicating 
detection of otherwise simple associations. More analy-
ses with larger and more carefully matched sequence sets 
may reveal further insight into the role of particular PNG 
sites in selection of T/F viruses.
CCR5 and CXCR4 utilization
Of all the phenotypic features of the T/F virus, CCR5 
utilization seems to be the most consistent. If specific 
viral sequences are selected for during transmission one 
would also then expect that the transmitted virus would 
favor interaction with specific cellular receptors and co-
receptors. Several research teams have shown that CCR5 
utilization is a key phenotype of the early transmitted 
virus [121, 122]. Keele et al. [8] showed that 98% of T/F 
viruses were CCR5 tropic. It was previously suggested 
that the CCR5 tropism of transmitted variants was due 
to the availability of macrophages at the site of trans-
mission. However, the apparent dependence upon high 
CD4 levels, and the similar macrophage infection capaci-
ties observed in chronic and T/F viruses, suggested that 
macrophages were unlikely to be the primary target cell 
during transmission [111, 123]. Nonetheless, others show 
primary infection of urethral macrophages, suggesting 
that the need for high levels of CD4 is not absolute [68].
Etemad et al. [124] took the V1–V5 region from early 
and chronic variants and cloned them into an iso-
genic HIV-1 backbone to generate chimeric infectious 
molecular clones (IMCs), the chronic infection variants 
replicated to higher titers in cells with lower CCR5 lev-
els compared to those from early infection, suggesting 
that T/F viruses might require higher levels of CCR5 for 
infection. However when Wilen et  al. [125] compared 
the envelopes from 24 T/F viruses to those of 17 from 
chronic infection in a pseudovirus assay for their abil-
ity to utilize CCR5, CD4+ T cells subset cell tropism, 
fusion kinetics and dendritic cell trans-infection, they 
only found that the transmitted variants were margin-
ally more sensitive to CD4 binding site antibodies than 
those from chronic infection. Comparing viral envelope 
proteins from acute and chronic infections (all subtype 
C), Ping et al. [106] reported that chronic variants were 
able to use both a maraviroc-sensitive and an alternative 
maraviroc-insensitive conformation of CCR5, confirm-
ing earlier work [126]. Overall, these conflicting results 
could suggest that CD4 and CCR5 levels are not impor-
tant for HIV-1 transmission. However, effects from the 
viral model used (i.e. pseudoviruses vs IMC’s), the study 
of different subtypes in different studies, and use of 
unmatched T/F and chronic samples (i.e. from different 
participants) may be part of what complicates drawing a 
firm conclusion.
Neutralization sensitivity
Autologous neutralizing antibodies are usually detectable 
only after the first few months of HIV-1 infection [100, 
127–129, 130]. Nonetheless, there is evidence that anti-
body-based selection sometimes exerts selective effects 
soon after transmission and before the neutralizing 
antibodies were detectable by pseudovirus-based assays 
[131]. The selective pressure of antibody persists for years 
in the chronic phase of HIV-1 infection [132]. Escape 
and production of new antibodies, from which the virus 
escapes again, occurs in iterative cycles [129, 133–135]. 
These cycles are also observed in experimental macaque 
models of HIV-1 infection [136].
Evidence from B cell depleted macaques suggests that 
the constant antibody pressure gives some protection 
to the host, including reduced viral load [137, 138] and 
protection from disease progression [138]. A third study 
showed no protection; however, the sham-depleted con-
trols did not develop detectable neutralizing response 
against the challenge virus or these responses were 
severely delayed [139]. In all cases, interpretation was 
complicated by the fact that complete depletions seem 
to be rarely achieved in macaques [137–139]. In any 
event, it seems clear that any protective effect of antibody 
is dwarfed by a substantial protective effect of CD8+ 
T cell responses [140]. Depletion of B cells in African 
green monkeys had no effect upon drops in CD4+T cells 
or (generally rare) progression to disease [141]. How-
ever, even CD8+ T cell depletion has little effect [142], 
despite overwhelming evidence for their importance in 
human HIV-1 infection. This, along with the rarity of 
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progression to disease [143] and different dynamics of 
infection [144, 145] in SIV-infected African green mon-
keys calls into question to what extent they are a useful 
model for HIV-1 infection in humans. Interestingly, in 
human HIV-1 infection, B cell depletion of an individual 
resulted in the temporary appearance of a neutralization-
sensitive variant associated with a higher viral load set 
point [146], suggesting a role for antibody in protection 
of humans.
Nonetheless, it is clear that presumably higher anti-
body pressure from more broadly neutralizing antibody 
responses does not result in protection from HIV-1 
disease. Time to disease progression was not longer in 
individuals with more broadly neutralizing antibody 
responses [147, 148]. Clearly, the levels and breadth of 
neutralizing antibodies achieved in human populations 
was not sufficient to force selection of HIV-1 variants 
that were less fit or otherwise less able to induce disease. 
There is some evidence that such breadth and potency 
is experimentally achievable [149, 150], although pre-
sumably higher than normally achieved during natural 
infection.
Although broadly neutralizing antibodies do not con-
fer protection on a human population level, neutralizing 
antibodies impose substantial selective pressure upon 
viral populations. It is possible that such pressure makes 
chronic viruses overall more resistant to antibody, par-
ticularly neutralizing antibody, than T/F viruses. There 
are two related, but separable measures of neutraliza-
tion resistance: (1) resistance to autologous antibody (of 
the donor in a transmission pair) or (2) overall resistance, 
usually measured with pools of serum or blood plasma 
[151, 152].
Viruses establishing new infections through the hetero-
sexual route were sensitive to antibodies obtained from 
the infecting donor [98,  105], but not more sensitive to 
a set of heterologous blood samples [153]. This sensitiv-
ity to donor antibodies was more apparent for subtype 
C virus [105] and not in a subtype B MSM cohort [110] 
where only 2/8 from the chronically infected source part-
ner showed increased neutralization sensitivity to autolo-
gous neutralization [110]. The reason for the discrepancy 
between the studies is not clear; the infecting clade and 
the primary mode of transmission were both different. 
Nonetheless, the subtype C results raise the possibility 
that a shift in selective milieu over transmission favored 
new founder isolates that were less resistant to the neu-
tralizing antibodies of the donor.
There is evidence to suggest that antibody can inhibit 
superinfection if the recipient has high titer neutraliz-
ing antibody directed against the superinfecting isolate. 
Two studies [75,  154] identified several superinfection 
pairs and showed that the recipient’s serum generally 
contained little neutralizing activity directed against 
the superinfecting viral population (usually ID50  <  100). 
The superinfecting variants were not more sensitive to 
a heterologous serum pool than viral isolates from the 
pre-superinfection lineage, suggesting that they were 
not overall more neutralization sensitive [154]. Delay in 
development of neutralizing antibody responses and a 
lower magnitude of neutralizing activity were noted prior 
to superinfection in the superinfected recipients, when 
compared to recipients that were never detectably super-
infected. This suggests that more robust neutralizing 
responses may have been protective [75]. It has been dif-
ficult to show stronger evidence that antibody can inhibit 
superinfection. This is because it has not been possible to 
compare to superinfecting viruses that failed to establish 
themselves. However, in the age of large deep sequenc-
ing projects, it is becoming possible to detect these failed 
superinfections [155]. Taken together with direct evi-
dence for superinfections that grow and eventually fail 
[155], these data strongly suggest that particular isolates 
can be efficiently selected against by antibodies that neu-
tralize them, and that isolates from chronic infection 
may have been iteratively selected to be neutralization 
resistant.
Replication capacity and infectivity
HIV-1 establishes initial foci of infection in the genital 
mucosa. It was therefore hypothesized that viruses with 
enhanced infectivity and/or replication capacity will be 
preferentially transmitted. Parrish et  al. [156] compared 
infectious molecular clones derived from chronic and 
acute infection and found that viruses from acute infec-
tion were on average 2 times more infectious yet did 
not find a difference in replication capacity. A potential 
confounder of this study was that these viruses were 
not derived from epidemiologically linked transmis-
sion pairs. Two subsequent studies, that used matched 
donor-recipient pairs, failed to show that transmission 
selects for viruses with increased infectivity and/or repli-
cation capacity [98, 157]. Both studies characterized only 
a limited number of donor and recipient viruses. Select-
ing only 1–8 viral variants per transmitting donor and 1 
variant per recipient might not have sufficient statistical 
power to reveal differences in infectivity or replicative 
capacity. Oberle et al. [157] measured replicative capac-
ity using bulk viral isolates from in vitro PBMC culture, 
which should represent part of the in vivo viral quasispe-
cies. Nonetheless, this might have selected for the out-
growth of viral variants fit for growth in culture (rather 
than in  vivo persistence in chronic infection or during 
transmission) or outgrowth of archived viruses that no 
longer represent the plasma virus at that particular time 
point. (See the next section below for further discussion 
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of potential technical differences between these reports.) 
Oberle et  al. wrote that their results “support(ed) the 
notion that, at least in subtype B infection HIV-1 trans-
mission is to a considerable extent stochastic,” which has 
generated some discussion [158, 159].
A recent study by Iyer and co-authors [160] circum-
vented these problems by generating 300 single genome 
viral isolates using limiting dilution from transmission 
pairs. Isolates were from plasma and genital secretions 
of chronically infected donors and from plasma of their 
matched recipients. Iyer et al. were thus able to plot the 
distribution of infectivities and replication capacities in 
the quasispecies of each donor and recipient pair. They 
convincingly show that donor plasma isolates exhibit 
a wide range of infectivities and replication capacities. 
Importantly, transmitted viruses are on average 3 times 
more infectious and replicate 1.2–1.7 times more effi-
ciently than the non-transmitted donor viruses. Interest-
ingly, overall, viruses derived from genital secretions did 
not show a statistically significant increase in replication 
capacity or infectivity as compared to their correspond-
ing donor plasma isolates, although a trend towards 
modestly increased infectivity could be seen. These data 
suggest that the recipient’s genital mucosa (or perhaps 
the subsequent establishment of the nascent systemic 
infection) selects for viruses with enhanced replication 
capacity.
Type 1 interferon sensitivity
Selection processes operating during transmission may 
favor viral variants able to resist attack from host innate 
immune responses found in the genital tract, such as 
type I interferons. It has been shown that T/F viral iso-
lates appear more resistant to IFN-α than viruses derived 
from chronic infection in some [156, 161] but not all 
studies [98, 157]. Plasmacytoid dendritic cells are rapidly 
recruited to new foci of SIV infection in the endocervi-
cal mucosa in macaques and secrete high levels of type 
I interferons and interferon-stimulated genes in the 
endocervical mucosa [62], which could be expected to 
limit viral replication or select for traits that promote 
interferon resistance. Additionally, topical application 
of IFN-β in rhesus macaques provided protection from 
infection [162], suggesting that the presence of type I 
interferons can induce a state in the female genital tract 
that protects against infection. Thus, it is plausible that 
part of the selection around the time of transmission may 
involve selection for growth in the presence of substantial 
levels of type I interferons in the genital tract. In contrast, 
during chronic infection, it is possible that the virus may 
have the opportunity to grow under conditions or at ana-
tomical sites in which type I interferons exert less of an 
effect upon viral population growth.
In addition to the assessments of replicative capac-
ity described above, Iyer et  al. [160] measured the inhi-
bition of IFNα2 and IFNβ upon primary HIV-1 isolates 
from transmission pairs. The interferon resistance of 
donor plasma-derived viruses varied over a wide range. 
In comparison, isolates from recently infected recipi-
ents were uniformly resistant to type I interferons, and 
were, on average, 7.8-fold and 39-fold more resistant to 
inhibition by IFNα2 and IFNβ, respectively, compared to 
donor isolates. A limited proportion of this selection may 
have occurred at the transition between donor circula-
tion (blood) and the donor genital tract, as suggested by 
a 2.5-fold increase in IFNβ resistance in genital tract iso-
lates. Presumably, the remainder of the transition occurs 
through the process of crossing the recipient genital 
mucosa, replicating there, and then establishing the new 
disseminated infection. This is in line with earlier results 
suggesting increased interferon resistance of recipient 
viruses compared to later chronic isolates from the same 
individuals [161, 163]. In contrast, Deymier et al. [98] did 
not observe any effect upon IFNα resistance and Oberle 
et al. [157] found recipient viruses to be modestly more 
sensitive to IFNα than their paired transmitter viruses. 
As noted above, these studies may have been limited 
in the number of viruses evaluated [98], or in the type 
of virus isolated [157], which could have impacted the 
results. In addition, both studies measured IFNα resist-
ance in response to a single dose of IFNα which may be 
less accurate than determining the IC50, as done by Iyer 
et al. [160]. Importantly, IFNα resistance is not necessar-
ily constantly low during chronic infection, but increases 
as patients approach progression to AIDS disease [164, 
165]; therefore, the difference in IFNα resistance may be 
sensitive to when during the course of infection a virus is 
transmitted. Finally, the mode of transmission might play 
a role, with Iyer et al. (4/7 transmissions were female-to-
male) evaluating more stringent and potentially more 
selective bottlenecks [97] as opposed to Oberle et  al. 
(mainly MSM) [157]. This would not explain the discrep-
ancy in conclusions with Deymier et  al. (5/6 transmis-
sions were female-to-male).
Virus release from infected cells and the role of vpu
Transmitted founder viruses were shown to exhibit 
higher virion release capacity than chronic control 
viruses [166]. This was confirmed in a much larger study 
on epidemiologically-linked transmission pairs showing 
that recipient isolates had 4.2-fold higher odds of virus 
release from infected cells than donor isolates. Interest-
ingly, donor viruses which were isolated in the presence 
of high levels of IFNs, also showed enhanced virus release 
as compared to untreated donor isolates [160]. These 
data suggest that the production of cell-free virus is a 
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determinant of IFN resistance, which, as described above, 
is important to overcome the innate immune response.
Virus release from infected cells is known to be 
restricted by the cellular restriction factor tetherin which 
is a protein-based tether that can retain HIV-1 virions on 
the cell surface [167]. HIV-1 has evolved Vpu proteins to 
counteract tetherin to significantly enhance virus rep-
lication and release in human CD4+ T cells particularly 
in the presence of IFNs [167]. Nonetheless, even in the 
absence of Vpu, T/F viruses still produce more cell-free 
viruses [166]. Moreover, in a study to determine the 
importance of Vpu activity in HIV-1 transmission, no dif-
ference was found in the functionality of Vpu from T/F 
isolates as compared to isolates from chronic infection 
[168]. This suggests that Vpu is not primarily responsible 
for the observed difference in HIV-1 particle release and 
that other factors presumably play a role.
Role of α4β7 integrin and gut‑associated lymphoid tissues 
(GALT) in HIV‑1 selection
A natural mechanism exists whereby white blood cells 
move from the genital tract to the gut associated lym-
phoid tissue (GALT) [169], which is a primary site of 
HIV-1 replication [170]. HIV-1 populations can use this 
mechanism to escape the genital tract. This is made 
possible by the ability of HIV-1 envelope to bind α4β7, 
an integrin homing receptor on the surface of activated 
CD4+ T cells [171], including those which are present 
at the site of sexual transmission [172] This happens 
within days of infection. The virus is transported to the 
Peyer’s patches and mesenteric lymph nodes where mas-
sive HIV-1 replication takes place [171, 173, 174]. Viruses 
with greater α4β7 binding capacity may therefore be 
selected for expansion in the gut. The selection in GALT 
has the potential to explain unexpectedly high frequen-
cies of single variant transmission reported in intrave-
nous drug users (IVDU) discussed above.
The ligands of α4β7 integrin bind to the HIV-1 gp120 
subunit of Envelope through a tripeptide motif with a 
central aspartic acid [175]. A similar binding site is often 
found in V2 region of HIV-1 gp120 at position 179–181 
(HXB2 numbering) with the aspartate at position 180 
being conserved across 98% HIV-1 isolates [171]. The 
consequence of infection of the GALT by HIV-1 is rapid 
depletion of T cells. Specifically, the depletion of the 
Th17 subset have been implicated in deterioration of the 
intestinal mucosa integrity and therefore leading to trans-
location of microbes and microbial components in the 
systemic circulation [169, 176] leading to immune activa-
tion. Binding of the gp120 to the α4β7 integrin is not an 
essential requirement as is the binding to CD4 receptor 
or the CCR5 co-receptor but it is thought to be important 
only in the early stages of HIV-1 infection [171]. In fact, 
is has recently been shown in an acute infection cohort 
that the interaction with α4β7 varied between isolates 
and within individuals over time [177]. Nevertheless, 
HIV-1 target cells with high concentration of α4β7 has 
been shown to be more susceptible to HIV-1 infection, 
a factor that may also be attributable to the high levels of 
CCR5 found in these cells as well [178]. In addition, pref-
erential infection of α4β7 expressing leukocytes would 
increase the chances of HIV-1 to be disseminated to the 
GALT. This may be a discrete trait; Nawaz et  al. [108] 
showed that shorter C3/V4 were associated with effi-
cient binding of HIV-1 to α4β7. A recent study has shown 
that challenging macaques intravenously with anti α4β7 
antibodies protects them from a repeated dose challenge 
with SIVmac251 infection due to their GALT being pro-
tected from infection [179–181]. In sum, α4β7 is used as 
an attachment factor that lowers the entropic barrier for 
binding of HIV-1 to CD4 and CCR5 which overall gives a 
selective advantage to the virus during the early stages of 
infection [177]. Some in vitro studies have failed to con-
firm the contribution of this integrin in HIV-1 infection 
[98, 163, 182, 183]. Nonetheless, much of the available 
evidence suggests that viruses with greater α4β7 binding 
capacity may be selected for expansion in the gut. Selec-
tion in GALT has the potential to explain unexpectedly 
high frequencies of single variant transmission reported 
in intravenous drug users (IVDU) discussed above.
Macrophage tropism
Unlike CD4+ T cells, macrophages have low levels of 
surface CD4 and have mostly been observed in the cen-
tral nervous system of infected patients [184, 185], late 
in disease [186] and more recently in the male geni-
tal compartment [187]. Probably the most well studied 
compartment as far as macrophage tropism is the cen-
tral nervous system which has 4 types of macrophages; 
microglia, meningeal macrophages, perivascular mac-
rophages and macrophages of the choroid-plexus [188]. 
The macrophage-tropic viruses use the CCR5 coreceptor 
for entry [189] and are more sensitive to inhibition by 
soluble CD4 and some mAb targeting the V1/V2 region 
[190]. The nature of the transmitted virus has also been 
studied in the context of macrophage tropism. Most of 
these in vitro studies have been done by infecting mono-
cyte-derived macrophages (MDMs) using HIV-1 iso-
lates, infectious molecular clones (IMCs) or pseudotyped 
viruses. More recently, some studies have used CD4 Affi-
nofile cells expressing low amounts of CD4 receptors as a 
surrogate for macrophage tropism [184]. The advantage 
of Affinofile cells is that they have inducible levels of CD4 
allowing one to vary them in testing for macrophage tro-
pism. Macrophage-tropic viruses are better at infecting 
cells with low levels of CD4. Earlier studies had indicated 
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that macrophage tropism was the nature of the trans-
mitted virus [2, 191] but more recent studies have sug-
gested that macrophage tropism [10, 192, 193] and low 
CD4 utilization [123, 163] may not be not necessary for 
transmission.
Impact of approaches used to study the 
transmitted virus upon discrepancies in character 
of the transmitted/founder (T/F) HIV‑1
There have been differing findings on the character and 
property of the T/F and acute infection viruses, poten-
tially obscuring our ability to identify specific properties 
linked to transmissibility or selection at transmission. 
These differing findings mainly originate from differences 
in the methodologies and experimental designs used in 
these studies although other factors like study popula-
tion, transmission risk factors, lab-to-lab definition of 
acute and chronic virus play part as well. The first prob-
lem is that there is approximately 10 days delay between 
the infection by the HIV-1 virus and the detection of the 
viral RNA in blood that makes it difficult to monitor the 
actual transmission process. Depending on when the 
actual virus was sampled, can lead to different conclu-
sions. The only way around this is to sample tissues on a 
regular basis, but this is highly invasive.
The second issue lies in the different approaches for 
sequencing HIV-1. In order to study selection of the 
transmitted virus in detail, samples are taken from the 
donor blood as well as from the recipient blood. This is 
followed by subcloning and bulk sequencing [194, 195], 
single genome amplification (SGA)-based analysis [6–8, 
93] or deep sequencing-based analysis [196]. Earlier 
studies of the T/F virus relied on collecting the sample 
material a few months following appearance of infec-
tion symptoms followed by bulk PCR-based methods, 
cloning, sequencing and phylogenetic analysis [27, 105, 
110, 194, 197, 198] or heteroduplex tracking assay (HTA) 
[194, 197, 198]. These studies reported that the transmit-
ted virus found in the acute phase of infection is homog-
enous as contrasted to more heterogeneous population 
found in the chronic infection and that the acute virus 
utilizes the CCR5 coreceptor [105, 194]. These and other 
[1, 2] early studies laid the groundwork supporting the 
conclusion that HIV-1 infection involves a transmission 
bottleneck.
Some of these early studies used samples that were 
several months post-transmission and this is too late to 
reliably capture the properties of the initial transmitted 
virus and reduce the likelihood of detecting multiple 
T/F viruses—on at least a theoretical level, the longer 
the time between transmission and sampling for these 
studies, the higher the likelihood that some of the ini-
tial T/F will be outcompeted and disappear. There are 
significant limitations to each of these approaches. 
The bulk PCR-based approaches are compromised by 
introduction of Taq polymerase-based errors due to 
lack of proof reading capability of the enzyme leading 
to incorporation of nucleotides on the sequence lead-
ing to exaggeration of the true diversity of the viral 
population. In addition, Taq polymerase-based tem-
plate switching caused by premature termination of the 
elongation step, products of which are used to prime 
the template in the subsequent PCR amplification step 
leading to artificial recombination in  vitro. Secondly, 
these approaches are also faced with a problem of tem-
plate resampling due to bias against or towards particu-
lar sequences, including unequal representation of the 
template in the sample. The template that is highly rep-
resented is the one that is usually amplified, making it 
difficult to detect templates represented in minor pop-
ulations. It has been reported that they miss the vari-
ants that are represented below 20% in frequency [199, 
200]. Further, cloning bias cannot be avoided, which 
results in an analysis skewed towards the variants that 
can be most easily cloned. The standard bulk sequenc-
ing thus does not accurately reflect viral diversity in an 
HIV-1 quasispecies.
SGA-based methods address some of these limita-
tions. In SGA, RNA or cDNA is serial diluted, in order 
to identify the dilution at which no more than 25 or 30% 
of PCR reactions are positive. In such cases, the sample 
is sufficiently diluted that most of the resulting amplifi-
cation products have been amplified from a single tem-
plate [7]. When only a single template gives rise to the 
PCR product, artificial recombination through template 
switching cannot happen. Also the effect of cloning bias 
is strongly reduced because different sequences are not 
competing in the same transformation and growth reac-
tion. However, this approach is very labor-intensive and 
reagent-intensive and is limited because it is expensive to 
generate and sequence very large numbers of clones.
Deep sequencing is the latest approach and affords 
the opportunity to handle a large data set that is a bet-
ter representation of the viral population in the infected 
donor or recipient and PCR is not needed before the 
library preparation step avoiding the serious artifacts of 
this step. It offers the great opportunity of studying the 
viral genetic diversity in unprecedented details that ear-
lier technologies couldn’t. Importantly, it also allows the 
use of primer IDs, which makes it possible to match each 
PCR product to its original template cDNA molecule 
generated in the reverse transcriptase reaction [196], 
and hence to calculate a consensus sequence for each 
cDNA used as a template for PCR, and to distinguish and 
account for template resampling and most PCR-based 
errors [196].
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Finally, the choice of cohort from which to study trans-
mitted viral isolates can lead to different results. In study-
ing T/F virus some research groups have followed linked 
transmitting pairs where the samples are obtained from 
blood of the donor and the recipient [17, 97, 98] while 
others have looked at sequence data of acutely infected 
people and a unlinked chronically infected cohorts [11, 
106, 156]. Both of these approaches have their advan-
tages and disadvantages. One of the advantages of fol-
lowing discordant couples is the opportunity to capture 
the virus near the time of transmission but it can take 
a long time to gather data from such a cohort [17]. On 
the other hand, gathering large sets of sequences from 
unlinked acute and chronic viruses results in a much 
greater statistical power to detect differences and often 
allows for deeper analysis and comparisons. Because of 
the very high level of heterogeneity of HIV-1, it becomes 
important that a large sample size is used in generalizing 
findings.
Conclusions
The HIV-1 transmission bottleneck is generally thought 
to originate primarily from the physical and immu-
nological properties of the recipient’s healthy genital 
mucosa [4, 10, 12, 201, 202]. The bottleneck was origi-
nally understood as a physical barrier that would prevent 
most viruses from infecting the new host, irrespective of 
viral characteristics. However, over the last several years 
it became apparent that the transmitted founder virus is 
rarely the dominant variant in the donor, suggesting that 
the transmission bottleneck is not entirely stochastic but 
also involves the selection of specific viral phenotypes 
[3, 4, 17, 156]. We have reviewed here the characteristics 
identified to date that appear to change between chronic 
and T/F isolates.
Notably, an apparent similar [12, 15] though perhaps 
less severe [14] bottleneck can be observed in intrave-
nous drug users (IVDU) suggesting that the transmission 
bottleneck does not absolutely require the physical bar-
rier and/or defenses of the mucosal surface of the recipi-
ent. The transmission bottleneck observed in IVDU may 
reflect selection that does not require the presence of a 
mucosal surface as a barrier to infection. Perhaps these 
selective events operate during the establishment of the 
new, nascent infection. Similar selective processes may 
operate after a sexually transmitted virus crosses the 
genital tract mucosal barriers (see Fig. 1). In addition, the 
observation that different HIV-1 lineages can frequently 
be found in the genital tract as compared to the blood 
[16–21], suggests that the transmission bottleneck of 
sexual transmission may not be confined to the recipient 
but may also sometimes extend to selective events in the 
donor.
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